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day; 1200 mg/day with add-in-medication) and pregabalin
(PG; 300 mg/day and 600 mg/day; 300 mg/day with add-in-
medication) for the treatment of post-herpetic neuralgia (PHN)
from the perspective of the German Sickness Funds. METHODS:
The costs and beneﬁts of gabapentin, PG and the lidocaine
plaster were calculated using a Markov model taking a six-
month time horizon. Transition probabilities were mainly based
on clinical trials identiﬁed through a systematic review. Missing
data, data on resource utilization and add-in/switch medication
were obtained from a Delphi panel. Cost data were taken from
ofﬁcial price lists. A modiﬁed TWIST (time without symptoms)
analysis was conducted to calculate the cost per additional
month with sufﬁcient pain relief and no intolerable side-effects.
RESULTS: Treatment with the lidocaine plaster costs a total of
€937 per patient, compared with €728 for generic gabapentin,
€875 for PG300 mg and dominated PG600 mg. Patients treated
with the lidocaine plaster spent an average of 4.06 months
(67.7% of the total treatment period) with adequate pain relief
and no intolerable side-effects, compared with 2.72 months
(45.3% of the total treatment period) for gabapentin, 3.02
months (50.3% of the total treatment period) for PG300 mg
and 3.22 months (53.7% of the total treatment period) for
PG600 mg. Lidocaine plaster therefore costs €156 per additional
month with sufﬁcient pain relief and no side-effects relative to
gabapentin, €60 relative to PG300 mg. The lidocaine plaster was
dominant over PG600 mg. Scenario analyses and extensive one-
way sensitivity analyses on all parameters including the time
horizon conﬁrmed the robustness of the results. CONCLU-
SIONS: Patients receiving the lidocaine 5% plaster for PHN
spend more time with sufﬁcient pain relief and no intolerable
side-effects than those treated with gabapentin or pregabalin.
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OBJECTIVES: To assess the cost-effectiveness of pregabalin
(PGB) and other add-on antiepileptic medicines over standard
therapy (ST) in patients with refractory partial epilepsy (RPE)
from the societal perspective in Finland. METHODS: A dynamic
simulation model was used to estimate outcomes and costs of a
hypothetical cohort of 1000 RPE patients over 1 year. Pregabalin
(PGB 300 mg/d) was compared to clinically and commercially
competitors: gabapentin (GBP 1800 mg/d), lamotrigine (LTG
300 mg/d), levetiracetam (LEV 2000 mg/d) and topiramate (TOP
200 mg/d). Number of seizure-free days (SFD) was used as an
outcome measure. Local costs of RPE medicines (excluding VAT)
and a specialist visit per a medicine switch were employed. Costs
per a SFD were calculated. To account for uncertainty around the
model estimates, the model was run for 50 samples. One-way
sensitivity analysis (PGB 600 mg/d, TOP 400 mg/d or employ-
ment of generic GBP price) was conducted. RESULTS: In com-
parison to ST, PGB (300 mg/d) yielded an average of additional
40 SFDs per a patient during a year. Incremental cost for PGB
was 29€ per a SFD (95%CI 23–36€). Corresponding estimate for
PGB (600 mg/d) was 44€ per a SFD whereas it varied 43–86€
among the comparators. At the dose of 600 mg/d, the PGB
incremental cost per a SFD was similar to GBP, but still lower
than among other comparators. CONCLUSION: Principal ﬁnd-
ings from the model suggest that PGB (300 mg/d) showed to be
a cost-effective add-on treatment for RPE patients in Finland
compared to ST. The incremental cost of PGB (300 mg/d) per a
SFD was lower than those of GBP, LTG and LEV with their
typical doses. One-way sensitivity analyses indicated that the
results were robust to plausible variations in the essential model
parameters, namely daily dose of PGB and TOP and price of
GBP.
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OBJECTIVES: To model the incremental cost-utility of Exelon
Patch versus best supportive care (BSC) in the management of
Alzheimer’s disease (AD), from the perspective of the UK NHS.
METHODS: The incremental costs and Quality Adjusted Life
Years (QALYs) associated with Exelon Patch treatment versus
BSC were calculated using an economic model. Changes in Mini
Mental State Examination (MMSE) scores over a 5-year period
were used as a measure of the progression of AD. The clinical
pathway was populated based on the results of the pivotal
IDEAL trial, with 12-month follow-up data from patients who
received Exelon Patch (n = 383) and 6-month follow-up data
from patients who received placebo (n = 282). The progression
of the disease was modelled beyond the study period using pub-
lished equations to predict the natural decline of MMSE in AD
patients. Costing variables included drugs, clinical monitoring
and institutionalisation. RESULTS: Exelon Patch was shown to
provide an incremental 0.1045 QALYs at an additional cost of
£1,363 per patient, giving a cost-utility of £13,042 per QALY
gained. One-way sensitivity analysis suggested that the main
determinants of cost-effectiveness were the probability of insti-
tutionalisation, the relationship between MMSE states and
quality of life, and the health economic perspective adopted.
When informal care costs were included in the analysis, Exelon
Patch was calculated to cost £634 per QALY gained. CONCLU-
SION: Exelon Patch has a superior cost-effectiveness proﬁle than
many treatments currently funded by the NHS. Further research
studies focusing on activities of daily living to demonstrate costs
and beneﬁts of treatment are warranted.
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OBJECTIVES: Evaluate the prevalence and costs of commonly
reported insomnia comorbidities. METHODS: A database of US
employees from 2001–2006 was used to identify subjects with
insomnia (based on the International Classiﬁcation of Diseases–9
[ICD-9] codes or prescription for a hypnotic agent) and control
employees (3:1) (matched by demographics, job information,
and geographic region). Direct medical costs (inﬂated to 2006
dollars) for each comorbid condition, based on ICD-9 codes
from the Agency for Health Research and Quality 261 Speciﬁc
Categories, were analyzed for the 12 months after insomnia
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